The molecular machinery of myelin gene transcription in schwann cells

GLIA

Volumn 56, Issue 14, 2008, Pages 1541-1551

  Svaren, John ^a   Meijer, Dies ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CMT; Egr2; Gene regulation; Peripheral neuropathy; Pou3f1; Sox10; Srebp

Indexed keywords

TRANSCRIPTION FACTOR;

ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; MYELIN SHEATH; MYELINATED NERVE; PERIPHERAL NERVOUS SYSTEM; PRENATAL DEVELOPMENT; REVIEW; SCHWANN CELL; SIGNAL TRANSDUCTION; ULTRASTRUCTURE;

ANIMALS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; MYELIN SHEATH; NERVE FIBERS, MYELINATED; PERIPHERAL NERVOUS SYSTEM; SCHWANN CELLS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 61449230512     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20767     Document Type: Article

References (111)

1. Arthur-Farraj P, Mirsky R, Parkinson DB, Jessen KR. 2006. A double point mutation in the DNA-binding region of Egr2 switches its function from inhibition to induction of proliferation: A potential contribution to the development of congenital hypomyelinating neuropathy. Neurobiol Dis 24:159-169.
2. Baranek C, Sock E, Wegner M. 2005. The POU protein Oct-6 is a nucleocytoplasmic shuttling protein. Nucleic Acids Res 33:6277-6286.
3. Bellone E, Di Maria E, Soriani S, Varese A, Doria LL, Ajmar F, Mandich P. 1999. A novel mutation (D305V) in the early growth response 2 gene is associated with severe Charcot-Marie-Tooth type 1 disease. Hum Mutat 14:353-354.
4. Bermingham JR Jr, Scherer SS, O'Connell S, Arroyo E, Kalla KA, Powell FL, Rosenfeld MG. 1996. Tst-1/Oct-6/SCIP regulates a unique step in peripheral myelination and is required for normal respiration. Genes Dev 10:1751-1762.
5. Bermingham JR Jr, Shearin H, Pennington J, O'Moore J, Jaegle M, Driegen S, van Zon A, Darbas A, Ozkaynak E, Ryu EJ, Milbrandt J, Meijer D. 2006. The claw paw mutation reveals a role for Lgi4 in peripheral nerve development. Nat Neurosci 9:76-84.
6. Bermingham JR Jr, Shumas S, Whisenhunt T, Sirkowski EE, O'Connell S, Scherer SS, Rosenfeld MG. 2002. Identification of genes that are downregulated in the absence of the POU domain transcription factor pou3f1 (Oct-6, Tst-1, SCIP) in sciatic nerve. J Neurosci 22:10217- 10231.
7. Bondurand N, Girard M, Pingault V, Lemort N, Dubourg O, Goossens M. 2001. Human Connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10. Hum Mol Genet 10:2783-2795.
8. Bowen NJ, Fujita N, Kajita M, Wade PA. 2004. Mi-2/NuRD: Multiple complexes for many purposes. Biochim Biophys Acta 1677:52-57.
9. Britsch S, Goerich DE, Riethmacher D, Peirano RI, Rossner M, Nave KA, Birchmeier C, Wegner M. 2001. The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev 15:66- 78.
10. Cosgaya JM, Chan JR, Shooter EM. 2002. The neurotrophin receptor p75NTR as a positive modulator of myelination. Science 298:1245- 1248.
11. Darbas A, Jaegle M, Walbeehm E, van den Burg H, Driegen S, Broos L, Uyl M, Visser P, Grosveld F, Meijer D. 2004. Cell autonomy of the mouse claw paw mutation. Dev Biol 272:470-482.
12. de Preux AS, Goosen K, Zhang W, Sima AA, Shimano H, Ouwens DM, Diamant M, Hillebrands JL, Rozing J, Lemke G, Beckmann JS, Smit AB, Verheijen MH, Chrast R. 2007. SREBP-1c expression in Schwann cells is affected by diabetes and nutritional status. Mol Cell Neurosci 35:525-534.
13. Decker L, Desmarquet-Trin-Dinh C, Taillebourg E, Ghislain J, Vallat JM, Charnay P. 2006. Peripheral myelin maintenance is a dynamic process requiring constant Krox20 expression. J Neurosci 26:9771- 9779.
14. Denarier E, Forghani R, Farhadi HF, Dib S, Dionne N, Friedman HC, Lepage P, Hudson TJ, Drouin R, Peterson A. 2005. Functional organization of a Schwann cell enhancer. J Neurosci 25:11210-11217.
15. Desmazieres A, Decker L, Vallat JM, Charnay P, Gilardi-Hebenstreit P. 2008. Disruption of Krox20-Nab interaction in the mouse leads to peripheral neuropathy with biphasic evolution. J Neurosci 28:5891- 5900.
16. Farhadi HF, Lepage P, Forghani R, Friedman HC, Orfali W, Jasmin L, Miller W, Hudson TJ, Peterson AC. 2003. A combinatorial network of evolutionarily conserved myelin basic protein regulatory sequences confers distinct glial-specific phenotypes. J Neurosci 23:10214-10223.
17. Feltri ML, D'Antonio M, Quattrini A, Numerato R, Arona M, Previtali S, Chiu SY, Messing A, Wrabetz L. 1999. A novel P0 glycoprotein transgene activates expression of lacZ in myelin-forming Schwann cells. Eur J Neurosci 11:1577-1586.
18. Feng Q, Zhang Y. 2003. The NuRD complex: Linking histone modification to nucleosome remodeling. Curr Top Microbiol Immunol 274:269-290.
19. Finzsch M, Stolt CC, Lommes P, Wegner M. 2008. Sox9 and Sox10 influence survival and migration of oligodendrocyte precursors in the spinal cord by regulating PDGF receptor alpha expression. Development 135:637-646.
20. Forghani R, Garofalo L, Foran DR, Farhadi HF, Lepage P, Hudson TJ, Tretjakoff I, Valera P, Peterson A. 2001. A distal upstream enhancer from the myelin basic protein gene regulates expression in myelinforming schwann cells. J Neurosci 21:3780-3787.
21. Friedrich RP, Schlierf B, Tamm ER, Bosl MR, Wegner M. 2005. The class III POU domain protein Brn-1 can fully replace the related Oct- 6 during schwann cell development and myelination. Mol Cell Biol 25:1821-1829.
22. Gao X, Daugherty RL, Tourtellotte WG. 2007. Regulation of low affinity neurotrophin receptor (p75(NTR)) by early growth response (Egr) transcriptional regulators. Mol Cell Neurosci 36:501-514.
23. Garcia-Dominguez M, Gilardi-Hebenstreit P, Charnay P. 2006. PIASxbeta acts as an activator of Hoxb1 and is antagonized by Krox20 during hindbrain segmentation. EMBO J 25:2432-2442.
24. Ghazvini M, Mandemakers W, Jaegle M, Piirsoo M, Driegen S, Koutsourakis M, Smit X, Grosveld F, Meijer D. 2002. A cell type-specific allele of the POU gene Oct-6 reveals Schwann cell autonomous function in nerve development and regeneration. EMBO J 21:4612-4620.
25. Ghislain J, Charnay P. 2006. Control of myelination in Schwann cells: A Krox20 cis-regulatory element integrates Oct6, Brn2 and Sox10 activities. EMBO Rep 7:52-58.
26. Ghislain J, Desmarquet-Trin-Dinh C, Jaegle M, Meijer D, Charnay P, Frain M. 2002. Characterisation of cis-acting sequences reveals a biphasic, axon-dependent regulation of Krox20 during Schwann cell development. Development 129:155-166.
27. Gillian AL, Svaren J. 2004. The Ddx20/DP103 dead box protein represses transcriptional activation by Egr2/Krox-20. J Biol Chem 279:9056-9063.
28. Guennoun R, Benmessahel Y, Delespierre B, Gouezou M, Rajkowski KM, Baulieu EE, Schumacher M. 2001. Progesterone stimulates Krox-20 gene expression in Schwann cells. Brain Res Mol Brain Res 90:75-82.
29. Howe DG, McCarthy KD. 2000. Retroviral inhibition of cAMP-dependent protein kinase inhibits myelination but not Schwann cell mitosis stimulated by interaction with neurons. J Neurosci 20:3513-3521.
30. Inoue K, Khajavi M, Ohyama T, Hirabayashi S, Wilson J, Reggin JD, Mancias P, Butler IJ, Wilkinson MF, Wegner M, Lupski JR. 2004. Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nat Genet 36:361-369.
31. Jaegle M, Ghazvini M, Mandemakers W, Piirsoo M, Driegen S, Levavasseur F, Raghoenath S, Grosveld F, Meijer D. 2003. The POU proteins Brn-2 and Oct-6 share important functions in Schwann cell development. Genes Dev 17:1380-1391.
32. Jaegle M, Mandemakers W, Broos L, Zwart R, Karis A, Visser P, Grosveld F, Meijer D. 1996. The POU factor Oct-6 and Schwann cell differentiation. Science 273:507-510.
33. Jaegle M, Meijer D. 1998. Role of Oct-6 in Schwann cell differentiation. Microsc Res Tech 41:372-378.
34. Jang SW, LeBlanc SE, Roopra A, Wrabetz L, Svaren J. 2006. In vivo detection of Egr2 binding to target genes during peripheral nerve myelination. J Neurochem 98:1678-1687.
35. Jessen KR, Mirsky R. 2005. The origin and development of glial cells in peripheral nerves. Nat Rev Neurosci 6:671-682.
36. Jones EA, Jang SW, Mager GM, Chang LW, Srinivasan R, Gokey NG, Ward RM, Nagarajan R, Svaren J. 2008. Interactions of Sox10 and Egr2 in myelin gene regulation. Neuron Glia Biology 3:377-387.
37. Jurevics HA, Morell P. 1994. Sources of cholesterol for kidney and nerve during development. J Lipid Res 35:112-120.
38. Kellerer S, Schreiner S, Stolt CC, Scholz S, Bosl MR, Wegner M. 2006. Replacement of the Sox10 transcription factor by Sox8 reveals incomplete functional equivalence. Development 133:2875-2886.
39. Koenig HL, Schumacher M, Ferzaz B, Thi AN, Ressouches A, Guennoun R, Jung-Testas I, Robel P, Akwa Y, Baulieu EE. 1995. Progesterone synthesis and myelin formation by Schwann cells. Science 268:1500-1503.
40. Kuhlbrodt K, Herbarth B, Sock E, Enderich J, Hermans-Borgmeyer I, Wegner M. 1998a. Cooperative function of POU proteins and SOX proteins in glial cells. J Biol Chem 273:16050-16057.
41. Kuhlbrodt K, Herbarth B, Sock E, Hermans-Borgmeyer I, Wegner M. 1998b. Sox10, a novel transcriptional modulator in glial cells. J Neurosci 18:237-250.
42. Le N, Nagarajan R, Wang JY, Araki T, Schmidt RE, Milbrandt J. 2005a. Analysis of congenital hypomyelinating Egr2Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell differentiation and myelination. Proc Natl Acad Sci USA 102:2596-2601.
43. Le N, Nagarajan R, Wang JY, Svaren J, LaPash C, Araki T, Schmidt RE, Milbrandt J. 2005b. Nab proteins are essential for peripheral nervous system myelination. Nat Neurosci 8:932-940.
44. LeBlanc SE, Jang SW, Ward RM, Wrabetz L, Svaren J. 2006. Direct regulation of myelin protein zero expression by the Egr2 transactivator. J Biol Chem 281:5453-5460.
45. Leblanc SE, Srinivasan R, Ferri C, Mager GM, Gillian-Daniel AL, Wrabetz L, Svaren J. 2005. Regulation of cholesterol/lipid biosynthetic genes by Egr2/Krox20 during peripheral nerve myelination. J Neurochem 93:737-748.
46. LeBlanc SE, Ward RM, Svaren J. 2007. Neuropathy-associated Egr2 mutants disrupt cooperative activation of myelin protein zero by Egr2 and Sox10. Mol Cell Biol 27:3521-3529.
47. Lee MM, Badache A, DeVries GH. 1999. Phosphorylation of CREB in axon-induced Schwann cell proliferation. J Neurosci Res 55:702-712.
48. Lee MM, Sato-Bigbee C, De Vries GH. 1996. Schwann cells stimulated by axolemma-enriched fractions express cyclic AMP responsive element binding protein. J Neurosci Res 46:204-210.
49. Leimeroth R, Lobsiger C, Lussi A, Taylor V, Suter U, Sommer L. 2002. Membrane-bound neuregulin1 type III actively promotes Schwann cell differentiation of multipotent progenitor cells. Dev Biol 246:245- 258.
50. Luciano RL, Wilson AC. 2003. HCF-1 functions as a coactivator for the zinc finger protein Krox20. J Biol Chem 278:51116-51124.
51. Mager GM, Ward RM, Srinivasan R, Jang SW, Wrabetz L, Svaren J. 2008. Active gene repression by the Egr2-NAB complex during peripheral nerve myelination. J Biol Chem 283:18187-18197.
52. Magnaghi V, Ballabio M, Roglio I, Melcangi RC. 2007. Progesterone derivatives increase expression of Krox-20 and Sox-10 in rat Schwann cells. J Mol Neurosci 31:149-157.
53. Mandemakers W, Zwart R, Jaegle M, Walbeehm E, Visser P, Grosveld F, Meijer D. 2000. A distal Schwann cell-specific enhancer mediates axonal regulation of the Oct-6 transcription factor during peripheral nerve development and regeneration. EMBO J 19:2992-3003.
54. Melcangi RC, Azcoitia I, Ballabio M, Cavarretta I, Gonzalez LC, Leonelli E, Magnaghi V, Veiga S, Garcia-Segura LM. 2003. Neuroactive steroids influence peripheral myelination: A promising opportunity for preventing or treating age-dependent dysfunctions of peripheral nerves. Prog Neurobiol 71:57-66.
55. Melcangi RC, Magnaghi V, Cavarretta I, Zucchi I, Bovolin P, D'Urso D, Martini L. 1999. Progesterone derivatives are able to influence peripheral myelin protein 22 and P0 gene expression: Possible mechanisms of action. J Neurosci Res 56:349-357.
56. Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave KA. 2004. Axonal neuregulin- 1 regulates myelin sheath thickness. Science 304:700-703.
57. Mikesova E, Huhne K, Rautenstrauss B, Mazanec R, Barankova L, Vyhnalek M, Horacek O, Seeman P. 2005. Novel EGR2 mutation R359Q is associated with CMT type 1 and progressive scoliosis. Neuromuscul Disord 15:764-767.
58. Monuki ES, Kuhn R, Lemke G. 1993. Repression of the myelin P0 gene by the POU transcription factor SCIP. Mech Dev 42:15-32.
59. Monuki ES, Kuhn R, Weinmaster G, Trapp BD, Lemke G. 1990. Expression and activity of the POU transcription factor SCIP. Science 249:1300-1303.
60. Monuki ES, Weinmaster G, Kuhn R, Lemke G. 1989. SCIP: A glial POU domain gene regulated by cyclic AMP. Neuron 3:783-793.
61. Morgan L, Jessen KR, Mirsky R. 1991. The effects of cAMP on differentiation of cultured Schwann cells: Progression from an early phenotype (041) to a myelin phenotype (P01, GFAP-, N-CAM-, NGF-receptor-) depends on growth inhibition. J Cell Biol 112:457-467.
62. Musso M, Balestra P, Bellone E, Cassandrini D, Di Maria E, Doria LL, Grandis M, Mancardi GL, Schenone A, Levi G, Ajmar F, Mandich P. 2001. The D355V mutation decreases EGR2 binding to an element within the Cx32 promoter. Neurobiol Dis 8:700-706.
63. Musso M, Balestra P, Taroni F, Bellone E, Mandich P. 2003. Different consequences of EGR2 mutants on the transactivation of human Cx32 promoter. Neurobiol Dis 12:89-95.
64. Nagarajan R, Le N, Mahoney H, Araki T, Milbrandt J. 2002. Deciphering peripheral nerve myelination by using Schwann cell expression profiling. Proc Natl Acad Sci USA 99:8998-9003.
65. Nagarajan R, Svaren J, Le N, Araki T, Watson M, Milbrandt J. 2001. EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. Neuron 30:355-368.
66. Nickols JC, Valentine W, Kanwal S, Carter BD. 2003. Activation of the transcription factor NF-kappaB in Schwann cells is required for peripheral myelin formation. Nat Neurosci 6:161-167.
67. Nikam SS, Tennekoon GI, Christy BA, Yoshino JE, Rutkowski JL. 1995. The zinc finger transcription factor Zif268/Egr-1 is essential for Schwann cell expression of the p75 NGF receptor. Mol Cell Neurosci 6:337-348.
68. Pareyson D, Taroni F, Botti S, Morbin M, Baratta S, Lauria G, Ciano C, Sghirlanzoni A. 2000. Cranial nerve involvement in CMT disease type 1 due to early growth response 2 gene mutation. Neurology 54:1696-1698.
69. Parkinson DB, Bhaskaran A, Arthur-Farraj P, Noon L, Woodhoo A, Lloyd AC, Feltri ML, Wrabetz L, Behrens A, Mirsky R, Jessen KR. 2008. c-Jun is a negative regulator of myelination. J Cell biol 181: 625-637.
70. Parkinson DB, Bhaskaran A, Droggiti A, Dickinson S, D'Antonio M, Mirsky R, Jessen KR. 2004. Krox-20 inhibits Jun-NH2-terminal kinase/ c-Jun to control Schwann cell proliferation and death. J Cell Biol 164:385-394.
71. Parkinson DB, Dickinson S, Bhaskaran A, Kinsella MT, Brophy PJ, Sherman DL, Sharghi-Namini S, Duran Alonso MB, Mirsky R, Jessen KR. 2003. Regulation of the myelin gene periaxin provides evidence for Krox-20-independent myelin-related signalling in Schwann cells. Mol Cell Neurosci 23:13-27.
72. Peirano RI, Goerich DE, Riethmacher D, Wegner M. 2000. Protein zero gene expression is regulated by the glial transcription factor Sox10. Mol Cell Biol 20:3198-3209.
73. Peirano RI, Wegner M. 2000. The glial transcription factor Sox10 binds to DNA both as monomer and dimer with different functional consequences. Nucleic Acids Res 28:3047-3055.
74. Pennuto M, Tinelli E, Malaguti M, Del Carro U, D'Antonio M, Ron D, Quattrini A, Feltri ML, Wrabetz L. 2008. Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in Charcot-Marie-Tooth 1B mice. Neuron 57:393-405.
75. Russo MW, Sevetson BR, Milbrandt J. 1995. Identification of NAB1, a repressor of NGFI-A- and Krox20-mediated transcription. Proc Natl Acad Sci USA 92:6873-6877.
76. Ryu EJ, Wang JY, Le N, Baloh RH, Gustin JA, Schmidt RE, Milbrandt J. 2007. Misexpression of Pou3f1 results in peripheral nerve hypomyelination and axonal loss. J Neurosci 27:11552-11559.
77. Saifi GM, Szigeti K, Snipes GJ, Garcia CA, Lupski JR. 2003. Molecular mechanisms, diagnosis, and rational approaches to management of and therapy for Charcot-Marie-Tooth disease and related peripheral neuropathies. J Invest Med 51:261-283.
78. Scherer SS, Wang DY, Kuhn R, Lemke G, Wrabetz L, Kamholz J. 1994. Axons regulate Schwann cell expression of the POU transcription factor SCIP. J Neurosci 14:1930-1942.
79. Schlierf B, Ludwig A, Klenovsek K, Wegner M. 2002. Cooperative binding of Sox10 to DNA: Requirements and consequences. Nucleic Acids Res 30:5509-5516.
80. Schreiner S, Cossais F, Fischer K, Scholz S, Bosl MR, Holtmann B, Sendtner M, Wegner M. 2007. Hypomorphic Sox10 alleles reveal novel protein functions and unravel developmental differences in glial lineages. Development 134:3271-3281.
81. Sereda MW, Meyer zu Horste G, Suter U, Uzma N, Nave KA. 2003. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 9:1533-1537.
82. Sevetson BR, Svaren J, Milbrandt J. 2000. A novel activation function for NAB proteins in EGR-dependent transcription of the luteinizing hormone beta gene. J Biol Chem 275:9749-9757.
83. Shen-Orr SS, Milo R, Mangan S, Alon U. 2002. Network motifs in the transcriptional regulation network of Escherichia coli. Nat Genet 31:64-68.
84. Sim FJ, Zhao C, Li WW, Lakatos A, Franklin RJ. 2002. Expression of the POU-domain transcription factors SCIP/Oct-6 and Brn-2 is associated with Schwann cell but not oligodendrocyte remyelination of the CNS. Mol Cell Neurosci 20:669-682.
85. Slutsky SG, Kamaraju AK, Levy AM, Chebath J, Revel M. 2003. Activation of myelin genes during transdifferentiation from melanoma to glial cell phenotype. J Biol Chem 278:8960-8968.
86. Sobue G, Shuman S, Pleasure D. 1986. Schwann cell responses to cyclic AMP: Proliferation, change in shape, and appearance of surface galactocerebroside. Brain Res 362:23-32.
87. Srinivasan R, Jang SW, Ward RM, Sachdev S, Ezashi T, Svaren J. 2007. Differential regulation of NAB corepressor genes in Schwann cells. BMC Mol Biol 8:117.
88. Srinivasan R, Mager GM, Ward RM, Mayer J, Svaren J. 2006. NAB2 represses transcription by interacting with the CHD4 subunit of the nucleosome remodeling and deacetylase (NuRD) complex. J Biol Chem 281:15129-15137.
89. Stolt CC, Lommes P, Friedrich RP, Wegner M. 2004. Transcription factors Sox8 and Sox10 perform non-equivalent roles during oligodendrocyte development despite functional redundancy. Development 131:2349-2358.
90. Svaren J, Sevetson BR, Apel ED, Zimonjic DB, Popescu NC, Milbrandt J. 1996. NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol Cell Biol 16:3545-3553.
91. Svaren J, Sevetson BR, Golda T, Stanton JJ, Swirnoff AH, Milbrandt J. 1998. Novel mutants of NAB corepressors enhance activation by Egr transactivators. EMBO J 17:6010-6019.
92. Swiers G, Patient R, Loose M. 2006. Genetic regulatory networks programming hematopoietic stem cells and erythroid lineage specification. Dev Biol 294:525-540.
93. Swirnoff AH, Apel ED, Svaren J, Sevetson BR, Zimonjic DB, Popescu NC, Milbrandt J. 1998. Nab1, a corepressor of NGFI-A (Egr-1), contains an active transcriptional repression domain. Mol Cell Biol 18:512-524.
94. Szigeti K, Garcia CA, Lupski JR. 2006. Charcot-Marie-Tooth disease and related hereditary polyneuropathies: Molecular diagnostics determine aspects of medical management. Genet Med 8:86-92.
95. Szigeti K, Wiszniewski W, Saifi GM, Sherman DL, Sule N, Adesina AM, Mancias P, Papasozomenos S, Miller G, Keppen L, Daentl D, Brophy PJ, Lupski JR. 2007. Functional, histopathologic and natural history study of neuropathy associated with EGR2 mutations. Neurogenetics 8:257-262.
96. Taveggia C, Pizzagalli A, Fagiani E, Messing A, Feltri ML, Wrabetz L. 2004. Characterization of a Schwann cell enhancer in the myelin basic protein gene. J Neurochem 91:813-824.
97. Taveggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S, Xu X, Esper RM, Loeb JA, Shrager P, Chao MV, Falls DL, Role L, Salzer JL. 2005. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron 47:681-694.
98. Timmerman V, De Jonghe P, Ceuterick C, De Vriendt E, Lofgren A, Nelis E, Warner LE, Lupski JR, Martin JJ, Van Broeckhoven C. 1999. Novel missense mutation in the early growth response 2 gene associated with Dejerine-Sottas syndrome phenotype. Neurology 52:1827-1832.
99. Topilko P, Levi G, Merlo G, Mantero S, Desmarquet C, Mancardi G, Charnay P. 1997. Differential regulation of the zinc finger genes Krox-20 and Krox-24 (Egr-1) suggests antagonistic roles in Schwann cells. J Neurosci Res 50:702-712.
100. Topilko P, Schneider-Maunoury S, Levi G, Baron-Van Evercooren A, Chennoufi AB, Seitanidou T, Babinet C, Charnay P. 1994. Krox-20 controls myelination in the peripheral nervous system. Nature 371:796-799.
101. Topilko P, Schneider-Maunoury S, Levi G, Trembleau A, Gourdji D, Driancourt MA, Rao CV, Charnay P. 1998. Multiple pituitary and ovarian defects in Krox-24 (NGFI-A, Egr-1)-targeted mice. Mol Endocrinol 12:107-122.
102. Verheijen MH, Chrast R, Burrola P, Lemke G. 2003. Local regulation of fat metabolism in peripheral nerves. Genes Dev 17:2450-2464.
103. Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L, Koob KG, Lupski JR. 1998. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 18:382-384.
104. Warner LE, Svaren J, Milbrandt J, Lupski JR. 1999. Functional consequences of mutations in the early growth response 2 gene (EGR2) correlate with severity of human myelinopathies. Hum Mol Genet 8:1245-1251.
105. Wegner M, Stolt CC. 2005. From stem cells to neurons and glia: A Soxist's view of neural development. Trends Neurosci 28:583-588.
106. Wissmuller S, Kosian T, Wolf M, Finzsch M, Wegner M. 2006. The high-mobility-group domain of Sox proteins interacts with DNA-binding domains of many transcription factors. Nucleic Acids Res 34:1735-1744.
107. Wrabetz L, D'Antonio M, Pennuto M, Dati G, Tinelli E, Fratta P, Previtali S, Imperiale D, Zielasek J, Toyka K, Avila RL, Kirschner DA, Messing A, Feltri ML, Quattrini A. 2006. Different intracellular pathomechanisms produce diverse myelin protein zero neuropathies in transgenic mice. J Neurosci 26:2358-2368.
108. Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, Kitabayashi I, Herr W, Cleary ML. 2004. Leukemia proto-Oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 24:5639-5649.
109. Yoon C, Korade Z, Carter BD. 2008. Protein kinase A-induced phosphorylation of the p65 subunit of nuclear factor-{kappa}B promotes Schwann cell differentiation into a myelinating phenotype. J Neurosci 28:3738-3746.
110. Zhong H, Voll RE, Ghosh S. 1998. Phosphorylation of NF-Kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1:661-671.
111. Zorick TS, Syroid DE, Brown A, Gridley T, Lemke G. 1999. Krox-20 controls SCIP expression, cell cycle exit and susceptibility to apoptosis in developing myelinating Schwann cells. Development 126:1397- 1406.